These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36946287)

  • 1. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
    Atzeni F; Gozza F; Riva A; Alciati A; Galloway J
    Expert Opin Pharmacother; 2023 Apr; 24(6):679-689. PubMed ID: 36946287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis.
    Alciati A; Di Carlo M; Siragusano C; Palumbo A; Masala IF; Atzeni F
    Expert Opin Biol Ther; 2022 Oct; 22(10):1311-1322. PubMed ID: 36168970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
    Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
    Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
    Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
    Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
    Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.
    Sánchez González CO; Nieto González JC
    Reumatol Clin (Engl Ed); 2022 Oct; 18(8):453-458. PubMed ID: 34893459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
    Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
    Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
    Källmark H; Bergström T; Nagel J; Gullstrand B; Einarsson JT; Bengtsson AA; Kapetanovic MC
    Rheumatology (Oxford); 2024 Jul; 63(7):2024-2033. PubMed ID: 37851412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
    Sonomoto K; Tanaka Y
    Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Cho SK; Kim H; Song YJ; Kim HW; Nam E; Lee SS; Lee HS; Park SH; Lee YA; Park MC; Chang SH; Kim HA; Kwok SK; Kim HR; Kim HS; Yoon BY; Uhm WS; Kim YG; Kim JH; Lee J; Choi J; Sung YK
    Korean J Intern Med; 2023 Jul; 38(4):546-556. PubMed ID: 37334513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.
    Popa CD; Opdam MAA; den Broeder N; van Ballegooijen H; Mulder K; van de Wiel KM; van Herwaarden N; Wientjes MHM; den Broeder AA
    Rheumatology (Oxford); 2024 Aug; 63(8):2142-2146. PubMed ID: 37796830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Janus kinase inhibitors on T cell responses to herpes zoster in rheumatoid arthritis patients.
    Lee JY; Kim SH; Lee SH; Kim HR; Min HK
    Clin Exp Rheumatol; 2023 May; 41(5):1077-1087. PubMed ID: 36062760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis.
    Ebina K
    Mod Rheumatol; 2022 Feb; 32(2):256-262. PubMed ID: 34894239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
    Alduraibi FK; Singh JA
    Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
    Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
    Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
    Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
    Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.